卵巢癌七种诊断策略的成本后果分析:基于模型的经济学评价
基于857例绝经前和1242例绝经后疑似卵巢癌症状女性的前瞻性单臂诊断准确性研究,构建决策树模型模拟12个月诊疗路径,比较七种诊断策略的成本与后果。结果显示无单一策略在所有结局上最优;IOTA ADNEX两步法10%阈值在成本、诊断产出和癌症死亡间提供最佳平衡,被推荐用于实践。
要点
- RMI 200成本最低但癌症死亡和诊断产出结局差
- ADNEX 3%诊断产出最高、癌症死亡最低但成本最高
- IOTA ADNEX两步法10%阈值在三项结局上均优于ORADS、ROMA和CA125
核心结论
- 12个月时无单一诊断策略在所有结局上占优,早期诊断需平衡癌症死亡、诊断产出和成本。
- IOTA ADNEX两步法10%阈值在这些因素间提供最佳权衡,被推荐用于实践。
研究设计与样本
- 基于前瞻性单臂诊断准确性研究的经济学评价,采用决策树模型模拟患者12个月诊疗路径。
- 样本为857例绝经前和1242例绝经后新发疑似卵巢癌症状至二级医疗的女性。
- 诊断准确性数据源自ROCkeTS研究并辅以文献补充。
主要发现
- 在两个队列中,RMI 200成本最低但癌症死亡和诊断产出结局差。
- ADNEX 3%策略诊断产出最高且癌症死亡最低,但成本最高。
- 绝经前女性中,IOTA ADNEX 10%策略在成本和结局上优于ORADS、ROMA和CA125。
- 绝经后女性因癌症患病率高需权衡取舍。
- 敏感性分析中,两步法IOTA ADNEX 10%策略在所有三项结局上优于ORADS、ROMA和CA125,在两个队列中均为更平衡的选择。
关键数值与推荐
- RMI 200:成本最低,癌症死亡和诊断产出结局差。
- ADNEX 3%:诊断产出最高,癌症死亡最低,成本最高。
- IOTA ADNEX 10%两步法:在成本、诊断产出和癌症死亡三项结局上均优于ORADS、ROMA和CA125。
临床怎么用
- 作者推荐将IOTA ADNEX两步法10%阈值用于实践,因其在癌症死亡、诊断产出和成本间提供最佳权衡。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the costs and consequences of seven diagnostic strategies for ovarian cancer in pre- and post-menopausal women with symptoms in secondary care. DESIGN: Economic evaluation alongside a prospective single-arm diagnostic accuracy study. SETTING: NHS secondary care outpatients (2-week referrals, clinics, GP referrals, cross-specialty referrals) and inpatients (emergency presentations to secondary care). SAMPLE: Two cohorts of 857 pre-menopausal and 1242 post-menopausal women newly presenting to secondary care with symptoms of suspected ovarian cancer. METHODS: A model-based cost-consequence analysis (CCA) was conducted using a decision tree simulating patient pathways over 12 months. Diagnostic accuracy data were sourced from the ROCkeTS study and supplemented by literature. MAIN OUTCOME MEASURES: Cancer deaths, correct diagnosis proportion, and diagnostic yield. RESULTS: No diagnostic strategy was optimal across all outcomes. Across both cohorts, the Risk of Malignancy Index (RMI) 200 was least expensive but had poor cancer death and diagnostic yield outcomes. The ADNEX 3% strategy had the highest diagnostic yield and lowest cancer mortality but was the most expensive. For pre-menopausal women, the IOTA ADNEX 10% strategy outperformed ORADS, ROMA, and CA125 in cost and outcomes. For post-menopausal women, the high cancer prevalence required a trade-off. In sensitivity analysis, a two-step IOTA ADNEX 10% strategy outperformed ORADS, ROMA, and CA125 across all three outcomes, making the strategy a more balanced choice in both cohorts. CONCLUSION: At 12 months, no single diagnostic strategy was superior. Early diagnosis requires balancing cancer mortality, diagnostic yield, and cost. The IOTA ADNEX two-step strategy at a 10% threshold provided the best trade-off across these factors and is recommended for practice.
引用
- Perry SJ, Griffin D, Williams EV, et al. A Cost Consequence Analysis of Seven Diagnostic Strategies for Ovarian Cancer: A Model-Based Economic Evaluation. BJOG. 2025. PMID: 41194592. doi:10.1111/1471-0528.70074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。